SCHEMBL24253161

SCHEMBL24253161

Cc1cc(O)ccc1CC(N)(CF)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 2/20 0.40
ODC1 P11926 1/20 0.36
HSD17B1 P14061 1/20 0.35
ESR2 Q92731 4/20 0.35
ESR1 P03372 2/20 0.35
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34
ALDH1A1 P00352 1/20 0.34
EGFR P00533 1/20 0.34
CYP1A2 P05177 1/20 0.34
FYN P06241 1/20 0.34
POLB P06746 1/20 0.34
CYP3A4 P08684 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
ALOX15 P16050 1/20 0.34
APEX1 P27695 1/20 0.34
ADRA1A P35348 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11327908 0.85 TYR (0.43) BLMODC1MEN1KMT2A
SCHEMBL11327906 0.85 TYR (0.43) BLMODC1MEN1KMT2A
SCHEMBL24253165 0.84 CHRNA7 (0.41) BLMODC1ESR2ESR1MEN1
SCHEMBL11089503 0.82 EGFR (0.40) BLMODC1ESR2ESR1KDM4E
SCHEMBL25596373 0.81 BLM (0.37) BLMHSD17B1ESR2ESR1KDM4E
SCHEMBL22074721 0.80 BLM (0.58) BLMHSD17B1ESR2ESR1KDM4E
SCHEMBL11236722 0.79 MAPT (0.37) BLMODC1KDM4EMEN1USP2
SCHEMBL11094621 0.77 ALDH1A1 (0.40) BLMODC1KDM4EALDH1A1EGFR
SCHEMBL4245716 0.74 BLM (0.59) BLMODC1ESR2ESR1KDM4E
SCHEMBL22033172 0.74 BLM (0.59) BLMODC1ESR2ESR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230181493-A1 BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME SENDA BIOSCIENCES INC (US) 2023-06-15 US disclosed
US-20230181493-A1 BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME SENDA BIOSCIENCES INC (US) 2023-06-15 US disclosed
US-20220048849-A1 DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE SENDA BIOSCIENCES, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048849-A1 DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE DDC, DDT, DDO BLM 2619/4885ODC1 8/4885HSD17B1 1156/4885
US-20230181493-A1 BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME COMT, SNCA, PARK7 BLM 3756/4885ODC1 273/4885HSD17B1 3924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.